It was standing room only at the campuses of Beth Israel Medical Center, St. Luke’s and Roosevelt Hospitals, and New York Eye and Ear Infirmary for a series of Town Hall meetings at which the leaders of the Mount Sinai Health System presented their vision for the future and how the new system will address today’s health care challenges.
As of September 11th 2013, BOTOX™ Cosmetic (onabotulinumtoxinA) received approval from the FDA for the treatment of lines extending around the corner of the eyes, commonly known as “crow’s feet.” Since its initial FDA approval in 2002, Botox has become incredibly popular for the treatment of facial lines and wrinkles, both on label (glabellar lines – the dreaded “11” seen between the eyebrows) and off-label (all the other lines and wrinkles on your face, including crows feet). Botox, along with its competitors and Dysport™ and Xeomin, are often referred to as “relaxing agents.” Technically, they are paralytic agents produced from sterile derivatives of Botulinum Toxin but most patients prefer not associate Botulism, toxins or paralysis with their face.
Liver cancer may be less well-known than other cancer types, but it is the fifth most common cancer in the world. And despite progress in other fields, liver cancer is one of the few cancers whose rate in the United States is continuing to rise. Liver cancer, whose medical term is hepatocellular carcinoma, is tumor that starts in the liver and can spread to other organs if left untreated.
The Boards of Trustees of The Mount Sinai Medical Center and Continuum Health Partners announced on Monday, September 30, the establishment of the Mount Sinai Health System. This new health system includes Icahn School of Medicine at Mount Sinai, seven major member hospital campuses in New York City, an extensive network of approximately 45 ambulatory care locations, 12 free-standing ambulatory surgery centers, and more than 40 clinical and academic relationships with local health care organizations—all throughout the greater metropolitan region.
The Mount Sinai Health System has launched a bold new era in community-based care that will provide world-class medical services to millions of people each year. Its vast geographic footprint includes seven member hospital campuses in Manhattan, from Chinatown to Chelsea, and midtown to Morningside Heights, as well as Queens and Brooklyn. It also extends into communities in each borough of New York City, Westchester, Long Island, and New Jersey.
The Icahn School of Medicine at Mount Sinai, one of the nation’s leading medical schools, along with its Graduate School of Biomedical Sciences, will serve to integrate all clinical and research missions for the seven member hospital campuses and vast network of ambulatory facilities in the new Mount Sinai Health System.